Abstract
This study was designed to assess the multiple steroid receptor mediated activities of a series of synthetic ‘progestins’ on breast cancer cell growth, using the human ZR-75-1 cell line which possesses functional estrogen (ER), androgen (AR), and glucocorticoid (GR) receptors as well as progesterone (PgR) receptors. Four 17-hydroxyprogesterone derivatives (chlormadinone acetate, CMA; cyproterone acetate, CPA; medroxyprogesterone acetate, MPA; and megestrol acetate, MGA) and two 19-nortestosterone derivatives (norethindrone, NRE, and norgestrel, NRG) were thus investigated.
Based on the requirement of estrogens for PgR-mediated antiproliferative effects and the reversal of PgR-mediated action by insulin, it was found that although all ‘progestins’ could inhibit ZR-75-1 cell growth through the PgR at low concentrations, the relative contribution of this receptor in cell growth control is highly variable between compounds. The quantitative importance of PgR-mediated inhibition of cell proliferation was inversely related to the amplitude of the androgenic effects induced by the compounds, the AR-mediated effects increasing in the order CPA < MGA < CMA < NRE < NRG < MPA. The specificity of these androgenic effects is further supported by their reversal upon addition of the antiandrogen hydroxyflutamide. In addition, the 17-hydroxyprogesterone derivatives, but not the 19-nortestosterone derivatives, had glucocorticoid activities at high (micromolar) concentrations, as shown by reversal of growth inhibition by the antagonist RU486 in the presence of saturating concentrations of 5α-dihydrotestosterone. All ‘progestins’ tested, except MPA and NRE, also had some antiglucocorticoid activity, NRG being the most potent in this respect. Finally, NRE and NRG exerted a marked mitogenic effect in estrogen-free medium which was clearly mediated through the ER as shown by the competitive reversal of their action by the steroidal antiestrogen EM-139.
The present results show that growth measurements of the human breast cancer cells ZR-75-1 permit, with the appropriate steroid additions, the assay of progestin, androgen, estrogen, and glucocorticoid agonistic as vell as antagonistic activities of test compounds. The present study shows, somewhat surprisingly, that while the AR is almost completely responsible for the action of MPA at low concentrations, the majority of the action of NRE, NRG, and MGA is also exerted through AR, while the androgenic action of CPA plays a lower role in the growth inhibition induced by this compound. Such a model should be of great help in designing more specific steroid drugs and in better understanding the role of the different steroid classes which can be used to control the growth of hormone-sensitive cancer. The present data also indicate that ‘progestin’ is an inappropriate name for MPA, NRE, NRG, MGA, CMA, and CPA, which all possess other and sometimes more potent steroidal activites than those related to interaction with the progesterone receptor.
Article PDF
Avoid common mistakes on your manuscript.
Abbreviations
- CMA:
-
chlormadinone acetate [17α-acetoxy-6-chloropregna-4, 6-dien-3, 20-dione]
- CPA:
-
cyproterone acetate [17α-acetoxy-6-chloro-1α,2α-methylene-pregna-4, 6-dien-3, 20-dione]
- DEX:
-
dexamethasone [9-fluoro-11β, 17, 21-trihydroxy-16α-methyl-pregna-1, 4-dien-3, 20-dione]
- DHT:
-
5α-dihydrotestosterone [17β-hydroxy-5β-androstan-3-one]
- E2 :
-
estradiol [estra-1, 3, 5 (10)-trien-3, 17β-diol]
- EM 139:
-
[N-n-butyl-N-methyl-11-(16α-chloro-3, 17β-dihydroxyestra-1, 3, 5 (10)-triene-7α-yl) undecanamide]
- MGA:
-
megestrol acetate [17α-acetoxy-6-methylpregna-4, 6-dien-3, 20-dionel]
- MPA:
-
medroxyprogesterone acetate [17α-acetoxy-6-methylpregn-4-en-3, 20-dione]
- NRE:
-
norethindrone [17β-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one]
- NRG:
-
norgestrel [13β-ethyl-17β-hydroxy-18, 19-dinor-17α-pregn-4-en-20-yn-3-one]
- OHF:
-
hydroxyflutamide (SCH 16423) [α, α, α-trifluoro-2-methyl-4′-nitro-m-lactotoluidide]
- R1881:
-
methyltrienolone [17β-hydroxy-17α-methyl estra-4, 9, 11-trien-3-one]
- R5020:
-
promegestone [17α, 21-dimethyl-19-norpregna-4, 9-dien-3, 20-dione]
- RU486:
-
[17β-hydroxy-11β-(4-dimethylaminophenyl)-17α-(1-propynyl)-estra-4, 9-dien-3-one]
- triamcinolone acetonide:
-
[9-fluoro-11β, 21-dihydroxy-16α, 17(1-methylethylidenebis 〈oxy〉) pregna-1, 4-dien-3, 20-dione]
References
Haller DG, Glick JH: Progestational agents in advanced breast cancer: an overview. Semin Oncol 13 (suppl): 2–8, 1986
Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1984
Horwitz KB, Wei LL, Sedlacek SM, d'Arville CN: Progestin action and progesterone receptor structure in human breast cancer: a review: Rec Progr Horm Res 41: 249–316, 1985
Huggins C, Yang NC: Induction and extinction of mammary cancer. Science 137: 257–262, 1962
Jabara AG: Effects of progesterone of 9,10-dimethylbenz-(a)anthracene in Sprague-Dawley rats. Br J Cancer 27: 63–71, 1973
Asselin J, Kelly PA, Caron MG, Labrie F: Control of hormone receptor levels and growth of 7,12-dimethylbenz-(a)anthracene-induced mammary tumors by estrogens, progesterone, and prolactin. Endocrinology 101: 666–671, 1977
Leung BS, Potter AH, Qureshi S: Interactions of prolactin, estrogen, and progesterone in a human mammary carcinoma cell line, CAMA-1-I. Cell growth and thymidine uptake. J Steroid Biochem 15: 421–427, 1981
Hissom JR, Moore MR: Progestin effects on growth in the human breast cancer cell line T-47D possible therapeutic implications. Biochem Biophys Res Commun 145: 706–711, 1987
Vignon F, Bardon S, Chalbos D, Rochefort H: Antiestrogenic effect of R5020, a synthetic progestin human breast cancer cells in culture. J Clin Endocrinol Metab 56: 1124–1130, 1983
Horwitz KB, Freidenberg GR: Growth inhibition and increase of insulin receptor in antiestrogen-resistant T47Dco human breast cancer cells by ‘progestins’: implications for endocrine therapies. Cancer Res 45: 167–173, 1985
Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38: 3352–3364, 1978
Poulin R, Dufour JM, Labrie F: Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin. Breast Cancer Res Treat 13: 265–276, 1989
Labrie F, Ferland L, Lagacé L, Drouin J, Asselin J, Azadian-Boulanger G, Raynaud JP: High inhibitory activity of R5020, a pure progestin, at the hypothalamic-adenohypophyseal level on gonadotropin secretion. Fertil Steril 28: 1104–1112, 1977
Raynaud JP, Ojasoo T, Labrie F: Steroid hormones agonists and antagonists. In: Lewis GP, Grisburg M (eds) Mechanisms of Steroid Action. MacMillan Press, London 1981, pp 145–158
Poyet P, Labrie F: Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate, and megestrol acetate. Mol Cell Endocrinol 42: 283–288, 1985
Labrie C, Cusan L, Plante M, Lapointe S, Labrie F: Analysis of the androgenic activity of synthetic ‘progestins’ currently used in the treatment of prostate cancer. J Steroid Biochem 28: 379–384, 1987
Poulin R, Baker D, Poirier D, Labrie F: Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 13: 161–172, 1989
Luthy IA, Bégin DJ, Labrie F: Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 31: 845–852, 1988
Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F: Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol Cell Endocrinol 68: 169–179, 1990
Pike MC, Chilvers C: Oral contraceptives and breast cancer: the current controversy. J Royal Soc Health 105: 5–10, 1985
Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19-Δ5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4937, 1986
Dickson RB, Lippman ME: Estrogenic stimulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8: 29–43, 1987
Poulin R, Baker D, Labrie F: Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12: 213–225, 1988
Osborne CK, Monaco ME, Kahn CR, Huff K, Bronzert D, Lippman ME: Direct inhibition of growth and antagonism by glucocorticoids in human breast cancer cells in culture. Cancer Res 39: 2422–2428, 1979
Sutherland RL, Hall RE, Pang GYN, Musgrove EA, Clarke CL: Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48: 5084–5091, 1988
Neri R, Peets E, Watnick A: Antiandrogenicity of flutamide and its metabolite SCH16423. Biochem Soc Trans 7: 565–569, 1979
Simard J, Luthy I, Guay J, Bélanger A, Labrie F: Characteristics of the interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261–270, 1986
Philibert D: RU38486: an original multifaceted antihormonein vivo. In: Agarwal MK (ed) Adrenal Steroid Antagonism. Walter de Gruyter, Berlin, 1984, pp 77–101
Danhaive PA, Rousseau GG: Binding of glucocorticoid antagonists to androgen and glucocorticoid hormone receptors in rat skeletal muscle. J Steroid Biochem 24: 481–487, 1986
Lévesque C, Mérand Y, Dufour JM, Labrie C, Labrie F: Synthesis and biological activity of new halosteroidal antiestrogens. J Med Chem, 1991, in press.
Hubert JF, Vincent A, Labrie F: Estrogenic activity of phenol red in rat anterior pituitary cells in culture. Biochem Biophys Res Commun 141: 885–891, 1986
Taylor CM, Blanchard B, Zava DT: A simple method to determine whole cell uptake of radiolabeled estrogens and progesterone and their subcellular localization in breast cancer cell lines in monolayer cultures. J Steroid Biochem 20: 1083–1088, 1984
Rodbard D: Apparent positive cooperative effect in cyclic AMP and corticosterone production by isolated adrenal cells in response to ACTH analogues. Endocrinology 94: 1427–1437, 1974
Cheng Y, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108, 1973
Munson PJ, Rodbard D: An exact correction to the ‘Cheng-Prusoff’ correction. J Receptor Res 8: 533–546, 1988
Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagacé L, Labrie F: Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125: 392–399, 1989
MacIndoe JH, Etre LA: An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab 53: 836–842, 1981
Vilchis F, Chavez B, Pérez AE, Garcia GA, Angeles A, Pérez-Palacios G: Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progesterone receptors. J Steroid Biochem 24: 525–531, 1986
Larrea F, Vilchis F, Chavez B, Pérez-Palacios G: The metabolism of 19-nor contraceptive ‘progestins’ modulates their biological activity at the neuroendocrine level. J Steroid Biochem 27: 657–663, 1987
Braselton WE, Lin TJ, Ellegood JD, Mills TM, Mahesh VB: Accumulation of norethindrone and individual metabolites in human plasma during short-term and long-term administration of a contraceptive dosage. Am J Obstet Gynecol 133: 154–169, 1979
Sahlberg BL, Landgren BM, Axelson M: Metabolic profiles of endogenous and ethynyl steroids in plasma and urine from women during administration of oral contraceptives. J Steroid Biochem 26: 609–617, 1987
Sahlberg BL: The characterization of sulfated metabolites of norethindrone in human milk after oral administration of contraceptive steroids. J Steroid Biochem 26: 481–485, 1987
Perel E, Daniilescu D, Kharlip L, Blackstein ME, Killinger DW: The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture. Mol Cell Endocrinol 41: 197–203, 1985
Gerhards E, Hecker W, Hitze H, Nieuweboer B, Bellman O: Zum Stoffwechsel von Norethisteron (17α-Äthinyl-4-östren-17β-ol-3-on) und diesowie D-Norgestrel (18-methyl-17α-Äthinyl-4-östren-17β-ol-3-on) beim Menschen. Acta Endocrinol (Copenh) 68: 219–248, 1971
Bullock LP, Bardin CW, Sherman MR: Androgenic, antiandrogenic, and synandrogenic actions of ‘progestins’: role of steric and allosteric interactions with androgen receptors. Endocrinology 103: 1768–1782, 1978
Sandberg AA, Kirdani RY: Metabolism of natural and synthetic steroids used in cancer treatment. Pharmac Ther 36: 263–307, 1988
Horwitz KB, Pike AW, Gonzalez-Allen C, Fennessey PV: Progesterone metabolism in T47Dco human breast cancer cells. II. Intracellular metabolic path of progesterone and synthetic progestins. J Steroid Biochem 25: 911–916, 1986
Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, Labrie F, Mormon JP: Steroid hormone receptors and pharmacology. J Steroid Biochem 12: 143–157, 1980
Blossey HC, Wander HE, Kobberling J, Nagel GA: Pharmacokinetic and pharmocodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54: 1208–1215, 1984
Clavel B, Pichon MF, Pallud C, Milgrom E: Estradiol and progesterone receptors content and response to norethisterone treatment in advanced breast cancer. Eur J Cancer Clin Oncol 18: 821–826, 1982
Alexieva-Figusch J, Blankenstein MA, Hop WCJ, Klijn JGM, Lamberts SWJ, de Jong FH, Docter R, Adlercreutz H, Van Gilse HA: Treatment of metastatic breast cancer patients with different dosages of megestrol acetate: dose relations, metabolism and endocrine effects. Eur J Cancer Clin Oncol 20: 33–40, 1984
Ettinger DS, Allegra J, Bertino JR, et al: Megestrol acetate vs. tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 13: 9–14, 1986
Alexieva-Figusch J, Teulings FAG, Hop WCJ, Blonk-van der Wijst J, van Gilse HA: Steroid receptors in megestrol acetate therapy. Rec Results Cancer Res 91: 253–258, 1984
Lundgren S, Kvinnsland S, Utaaker E: Oral high-dose progestins as treatment for advanced breast cancer. Acta Oncol 28: 811–816, 1989
Wanger HE, Blossey Ch, Köbberling J, Nagel GA: Hochdosiertes Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: Beziehung zwischen Krankheitsverlauf und Hormonprofilen. Klin Wochenschr 61: 553–560, 1983
Earl HM, Rubens RD, Knight RK, Hayward JL: Norethisterone acetate in the treatment of advanced breast cancer. Clin Oncol 10: 103–109, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poulin, R., Baker, D., Poirier, D. et al. Multiple actions of synthetic ‘progestins’ on the growth of ZR-75-1 human breast cancer cells: Anin vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Tr 17, 197–210 (1991). https://doi.org/10.1007/BF01806369
Issue Date:
DOI: https://doi.org/10.1007/BF01806369